glp 1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research Liraglutide is a GLP-1 Receptor
Description
Obesity occurs in conditions with excess secretion of glucocorticoids such as Cushing syndrome
Injection site reactions occur in 14% of users, typically presenting as mild redness, itching, or temporary discomfort at the injection location
Effects of glucose-dependent insulinotropic peptide on behavior
In a post hoc analysis of the SURPASS-1 trial involving patients with T2DM, the percentage increase in adiponectin levels from baseline ranged from 16% to 23% with tirzepatide compared to a decrease of 0.2% with placebo at week 40 (190)
